openPR Logo
Press release

Epithelioid sarcoma Market, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight

04-12-2022 10:21 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Epithelioid sarcoma Market

Epithelioid sarcoma Market

Epithelioid sarcoma is a rare, malignant, slow-growing type of soft-tissue cancer. It begins as a slow growing, firm lump in the deep soft tissue or skin of arms, hands and fingers. It also occurs in legs, neck, and head. The lumps are usually painless, but sometimes this sarcoma appears as ulcers which don't even heal. It tends to have a high recurrence rate.

DelveInsight's "Epithelioid Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Epithelioid Sarcoma, historical and forecasted epidemiology as well as the Epithelioid Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To know about the Epithelioid sarcoma market report: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of Epithelioid sarcoma Market are:

• Epithelioid sarcoma is a mesenchymal soft tissue sarcoma often arising in the extremities, usually in young adults with a pick of incidence at 35 years of age.
• The Epithelioid sarcoma incidence rate is 0.03/100,000 in the European Union and 0.05/10,000 in the USA as per RARECAREnet and the SEER18 cancer registries.
• Epithelioid sarcomas are rare, representing less than 1% of soft tissue sarcomas, and have a predilection for men (up to 2:1 male to female ratio). Most reported tumors occur in young males ranging in age from 10 to 45 years. The extremes of ages include ages 4 to 90, with a median age of 27 years.

Request for Sample Report: https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of Epithelioid sarcoma Market Report:

• The report covers the descriptive overview of Epithelioid Sarcoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Epithelioid Sarcoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Epithelioid Sarcoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Epithelioid Sarcoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epithelioid Sarcoma market

To know about the detailed Coverage of the report: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of Epithelioid sarcoma Companies in Market are:
• Epizyme, Inc.
• Analysis Group, In
• WEP Clinical
• Amgen
• Merck Sharp & Dohme Corp.
• And Others

Request for Sample Report: https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market

Epithelioid sarcoma Drugs are:
• Tazemetostat
• Doxorubicin
• Talimogene Laherparepvec
• And Many Others

Request for Detailed Pipeline Analysis: https://www.delveinsight.com/report-store/epithelioid-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents:
1. Key Insights
2. Executive Summary of Epithelioid sarcoma
3. Competitive Intelligence Analysis for Epithelioid sarcoma
4. Epithelioid sarcoma: Market Overview at a Glance
5. Epithelioid sarcoma: Disease Background and Overview
6. Patient Journey
7. Epithelioid sarcoma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Epithelioid sarcoma Unmet Needs
10. Key Endpoints of Epithelioid sarcoma Treatment
11. Epithelioid sarcoma Marketed Products
List to be continued in report
12. Epithelioid sarcoma Emerging Therapies
List to be continued in report
13. Epithelioid sarcoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Epithelioid sarcoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Request for Detailed TOC: https://www.delveinsight.com/sample-request/epithelioid-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Epithelioid sarcoma Market, Epidemiology, Pipeline Therapies, Treatment and Companies by DelveInsight here

News-ID: 2600799 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Epithelioid

Epithelioid Sarcoma Market is expected to reach USD 1.2 billion by 2034
Epithelioid sarcoma is a rare and aggressive form of soft tissue sarcoma that typically affects young adults and adolescents. Despite being classified as a soft tissue cancer, it is notorious for its high recurrence rate and metastasis, often posing challenges in treatment and long-term survival. Standard therapies such as surgical resection and chemotherapy have been the mainstay, but recent advances in targeted therapies, immunotherapies, and rare disease research incentives are
Perivascular Epithelioid Cell Tumor Market Size, Share and Growth Report, 2034
Introduction Perivascular epithelioid cell tumors (PEComas) are a rare group of tumors characterized by the presence of epithelioid cells and smooth muscle components. These tumors can arise in various organs, including the lungs, kidneys, liver, and soft tissues, and are often classified as benign or malignant based on their characteristics. While PEComas are uncommon, they present unique challenges for diagnosis and treatment due to their heterogeneous nature. The tumors can exhibit
Epithelioid Sarcoma Market Future Business Opportunities 2025-2032 | Epizyme, El …
The epithelioid sarcoma market is estimated to be valued at USD 1.57 Bn in 2025 and is expected to reach USD 2.93 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.3% from 2025 to 2032. According to the latest research from CoherentMI, the Epithelioid Sarcoma Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough
Epithelioid Sarcoma Treatment: Advancements and Emerging Trends in Rare Cancer C …
Epithelioid sarcoma is a rare type of soft tissue cancer that primarily affects young adults and tends to appear in the extremities, such as hands and arms. This cancer type is known for its challenging diagnosis, high recurrence rate, and complex treatment requirements. Because epithelioid sarcoma is a rare and aggressive form of cancer, its treatment landscape has evolved rapidly in recent years, bringing new therapies and approaches to patients.
Epithelioid Sarcoma Treatment Market: A Comprehensive Overview
1. Introduction Epithelioid sarcoma (ES) is a rare and aggressive soft tissue sarcoma, predominantly affecting young adults. It has a propensity for recurrence and metastasis, often posing significant challenges for effective treatment. The complexities surrounding epithelioid sarcoma have driven innovations in the treatment landscape, sparking considerable growth and evolution in the global market for ES therapies. The global epithelioid sarcoma treatment market is shaped by several factors including advancements in therapeutic
Epithelioid Sarcoma Treatment Market Booming Worldwide With Leading Key Players …
The global Epithelioid Sarcoma Treatment Market was valued at $1.32 billion in 2023 and is projected to grow to $2.66 billion by 2031, with a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. DataM Intelligence has released a new research report on "Asia Latin America And Middle East Marine Generator Set Market Size 2024." This report offers in-depth insights into key factors such as regional growth, segmentation,